INT21712

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 1990
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 32
Total Number 33
Disease Relevance 21.64
Pain Relevance 2.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (APOA1) small molecule metabolic process (APOA1) extracellular region (APOA1)
plasma membrane (APOA1) enzyme binding (APOA1) transmembrane transport (APOA1)
Anatomy Link Frequency
adipocytes 3
plasma 1
blood 1
macrophage 1
BFA 1
APOA1 (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 406 100.00 Very High Very High Very High
imagery 30 99.44 Very High Very High Very High
agonist 35 98.16 Very High Very High Very High
methotrexate 17 95.76 Very High Very High Very High
Inflammation 105 95.40 Very High Very High Very High
Clonidine 5 91.76 High High
cytokine 113 89.60 High High
fibrosis 99 86.48 High High
Multiple sclerosis 10 84.36 Quite High
corticosteroid 11 80.40 Quite High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 878 100.00 Very High Very High Very High
Rheumatoid Arthritis 408 100.00 Very High Very High Very High
Disease 215 100.00 Very High Very High Very High
Coronary Artery Disease 403 99.66 Very High Very High Very High
Hyperlipoproteinemia Type Ii 15 98.32 Very High Very High Very High
Obesity 446 97.96 Very High Very High Very High
Sepsis 1 96.04 Very High Very High Very High
INFLAMMATION 110 95.40 Very High Very High Very High
Pressure And Volume Under Development 34 91.88 High High
Mental Disorders 4 91.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
While there was no significant change in apolipoprotein A levels with atorvastatin monotherapy (+1.5%, p = 0.493), there was a small, albeit statistically significant increase in apolipoprotein A levels in the combination therapy group (+4.5%, p = 0.041).
Positive_regulation (increase) of apolipoprotein A associated with disorder of lipid metabolism
1) Confidence 0.67 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2803170 Disease Relevance 0.68 Pain Relevance 0
Atenolol also induced a significant adverse effect on all lipid ratios, increasing total cholesterol/high density lipoprotein-cholesterol, low density lipoprotein-cholesterol/high density lipoprotein-cholesterol, apolipoprotein B/apolipoprotein A-I and apolipoprotein B/apolipoprotein A-II ratios and decreasing low density lipoprotein-cholesterol/apolipoprotein-B ratio (p less than 0.05).
Positive_regulation (increasing) of apolipoprotein A-I associated with disorder of lipid metabolism
2) Confidence 0.49 Published 1990 Journal Am. Heart J. Section Abstract Doc Link 2193493 Disease Relevance 1.13 Pain Relevance 0.38
Rosuvastatin also produced significantly greater reductions in apolipoprotein-B, as well as a significantly greater increase in apolipoprotein A-I.
Positive_regulation (increase) of apolipoprotein A-I associated with disorder of lipid metabolism
3) Confidence 0.49 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2672446 Disease Relevance 1.13 Pain Relevance 0
The population average ApoB/ApoA1 ratio (BARP) can be estimated from values for the age and gender-adjusted estimates of TC and HDL using the coefficients in Additional file 1, thus:
Positive_regulation (estimated) of ApoA1 associated with disorder of lipid metabolism
4) Confidence 0.48 Published 2008 Journal BMC Med Inform Decis Mak Section Body Doc Link PMC2601038 Disease Relevance 1.43 Pain Relevance 0
The population average ApoB/ApoA1 ratio (BARP) can be estimated from values for the age and gender-adjusted estimates of TC and HDL using the coefficients in Additional file 1, thus:
Positive_regulation (population) of ApoA1 associated with disorder of lipid metabolism
5) Confidence 0.48 Published 2008 Journal BMC Med Inform Decis Mak Section Body Doc Link PMC2601038 Disease Relevance 1.44 Pain Relevance 0
Only rosuvastatin treatment significantly reduced fasting LDL cholesterol, apolipoprotein B-100, apolipoprotein C-III, apolipoprotein C-III:B particles, the apolipoprotein B-100:apolipoprotein A-I ratio, and increased apolipoprotein A-I.
Positive_regulation (increased) of apolipoprotein A-I associated with disorder of lipid metabolism
6) Confidence 0.45 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2672446 Disease Relevance 0.86 Pain Relevance 0
Another potential target for raising HDL-C levels is augmenting ApoA-I levels (an important protein in HDL-C).
Positive_regulation (augmenting) of ApoA-I associated with disorder of lipid metabolism
7) Confidence 0.45 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 1.00 Pain Relevance 0.07
Dalcetrapib increased HDL-C (33.4%, Week 24; 33.8%, Week 48), decreased CETP activity (–53.5%, Week 24; –56.5%, Week 48), and increased apolipoprotein A-I (11.4%, Week 24; 16.4%, Week 48).
Positive_regulation (increased) of apolipoprotein A-I associated with disorder of lipid metabolism
8) Confidence 0.45 Published 2010 Journal European Heart Journal Section Abstract Doc Link PMC2821630 Disease Relevance 0.34 Pain Relevance 0.05
Combination therapy with ezetimibe plus fenofibrate did produce small, albeit statistically significant increases in apolipoprotein A levels, while none were observed with atorvastatin monotherapy.
Positive_regulation (increases) of apolipoprotein A associated with disorder of lipid metabolism
9) Confidence 0.45 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2803170 Disease Relevance 0.35 Pain Relevance 0
Dalcetrapib increased HDL-C (33.4%, Week 24; 33.8%, Week 48), decreased CETP activity (–53.5%, Week 24; –56.5%, Week 48), and increased apolipoprotein A-I (11.4%, Week 24; 16.4%, Week 48).
Positive_regulation (increased) of apolipoprotein A-I associated with disorder of lipid metabolism
10) Confidence 0.45 Published 2010 Journal European Heart Journal Section Abstract Doc Link PMC2821630 Disease Relevance 0.35 Pain Relevance 0.05
Laboratory testing showed a significant decrease in homocysteine (P = 0.05), HDL cholesterol (P = 0.025) and Apo A (P = 0.004), as well as a significant increase in ?
Positive_regulation (increase) of Apo A associated with disorder of lipid metabolism
11) Confidence 0.45 Published 2007 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Abstract Doc Link PMC2176151 Disease Relevance 0.50 Pain Relevance 0
In group B all blood lipid concentrations except apoA1 were increased after the test period and the increase in HDL by 4,8% was statistically different (p = 0,018) compared to starting values.
Positive_regulation (increased) of apoA1 in blood associated with disorder of lipid metabolism
12) Confidence 0.41 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2768711 Disease Relevance 0.58 Pain Relevance 0
Moreover, this release is not linked to the transcriptional regulation of the ABCA1 gene, because apoA-I induced efflux does not lead to an increase in ABCA1 gene expression (figure 1).
Neg (not) Positive_regulation (induced) of apoA-I
13) Confidence 0.40 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 0.36 Pain Relevance 0
Nonetheless, it should be mentioned that the statins are highly efficient on adipose cells, because after 24 hours of treatment, the basal or apoA-I induced cholesterol detected in the culture medium strongly decreases (data not shown).
Positive_regulation (induced) of apoA-I
14) Confidence 0.40 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 0.07 Pain Relevance 0
Indeed, following treatment for 12 hours, BFA inhibits approximately 30% of the basal cholesterol release and 35% of the apoA-I stimulated cholesterol release.
Positive_regulation (stimulated) of apoA-I in BFA
15) Confidence 0.40 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 0.24 Pain Relevance 0
Previous studies have shown that apoA-I induces an increase in ABCA1 phosphorylation, as well as an increase in the intracellular levels of cAMP [19], suggesting that the stimulatory effect of apoA-I could be related to cAMP, and thus to PKA [12,13].
Positive_regulation (effect) of apoA-I
16) Confidence 0.40 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 0.22 Pain Relevance 0
In order to determine whether the apoA-I induced efflux derives from a regulatory pool of cholesterol and is therefore associated with an increase in HMG-CoA reductase activity, we treated the adipocytes with a statin, which is a known inhibitor of this enzyme.
Spec (whether) Positive_regulation (induced) of apoA-I in adipocytes associated with obesity
17) Confidence 0.40 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 0.31 Pain Relevance 0
The overall evidence collected suggests that the increase in apoA-I induced cholesterol efflux is mediated by a particular pathway in human adipocytes.
Positive_regulation (increase) of apoA-I in adipocytes associated with obesity
18) Confidence 0.37 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 0.47 Pain Relevance 0
Figure 1 clearly shows that apoA-I increases in a dose dependent manner the release of cholesterol from mature human adipocyte cultures (panel A).
Positive_regulation (increases) of apoA-I in adipocyte
19) Confidence 0.37 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 0.18 Pain Relevance 0
A complex pattern of gene expression has been demonstrated through in vivo studies, wherein the Apo CIII enhancer acts as a common regulatory element for the APOA1-C3-A4 genes but not for the APOA5 gene [5].
Positive_regulation (acts) of APOA1
20) Confidence 0.37 Published 2008 Journal Lipids Health Dis Section Body Doc Link PMC2556320 Disease Relevance 0.66 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox